Aqilion PKCtheta inhibitor

Aqilion's PKCtheta program is an early-stage research initiative focused on developing small molecule inhibitors of Protein Kinase C theta (PKCtheta). PKCtheta is a member of the PKC family primarily expressed in T-cells and muscle, playing a pivotal role in T-cell receptor (TCR) signaling and activation. By inhibiting PKCtheta, the program aims to modulate T-cell mediated inflammatory responses, which are central to the pathogenesis of autoimmune diseases such as ulcerative colitis and rheumatoid arthritis. The program is currently in the lead optimization phase, seeking to identify a clinical candidate that can leverage the company's expertise in kinase inhibitor development for chronic inflammatory conditions.

Other names

PKCtheta programAqilion-PKCtheta-small molecule-ulcerative colitis-rheumatoid arthritis